COSCIENS Biopharma Inc T.AEZ

Primary Symbol: T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Jul 10, 2024 6:46pm

124 Views

Post# 36127371

Ronnie Miller's impact on Roche Canada's R&D initiatives

Ronnie Miller said that with the completion of the merger with AEZS the company was now optimized to bring transformational products to the market. Here's Ronnie Miller's background in R&D initiatives at Roche Canada.

Ronnie Miller's leadership had a significant impact on Roche Canada's R&D initiatives:

He played a key role in expanding Roche Canada's research footprint. In 2011, Miller oversaw the introduction of a Global Pharmaceutical Development site in Canada, which took on a leadership role in worldwide clinical trials.
This expansion involved a substantial investment of over $190 million in Ontario, growing the Pharmaceutical Development team from 76 to 236 people.
Miller was instrumental in securing government support for this expansion, with the Government of Ontario investing $7.79 million to support the project.
Under his leadership, Roche Canada developed a strong research presence in the country. Miller noted that Canada was recognized as "a great research country" that continues to conduct excellent research and science.
He fostered a shift towards personalized medicine and biomarker-based diagnosis, reflecting the evolving understanding of genomics and the application of data analytics in healthcare.
Miller initiated the CARE (Clinical Analytics and Real World Evidence) project in collaboration with the University of Waterloo and Princess Margaret Hospital, focusing on using real-world evidence and data analytics to improve clinical studies and treatment outcomes.
He led Roche Canada's participation in the federal government's 'Supercluster Initiative', collaborating with other pharmaceutical companies and tech giants to advance data analytics in healthcare.
Miller's leadership emphasized the importance of partnerships in research, collaborating with academic institutions, hospitals, and other industry players to drive innovation in the Canadian healthcare space.

These initiatives demonstrate how Miller's leadership significantly expanded Roche Canada's R&D capabilities, fostered collaborations, and positioned the company at the forefront of innovative research in personalized medicine and data analytics in healthcare.